<DOC>
	<DOCNO>NCT00136422</DOCNO>
	<brief_summary>The purpose study test safety new investigational acute myeloblastic leukemia ( AML ) vaccine see effect ( good bad ) patient advanced myelodysplasia acute myelogenous leukemia .</brief_summary>
	<brief_title>Study Vaccination With Autologous Acute Myeloblastic Leukemia Cells Patients With Advanced Myelodysplasia Acute Myelogenous Leukemia</brief_title>
	<detailed_description>This study make use leukemic myeloblast harvest bone marrow aspirate patient myelodysplasia acute myelogenous leukemia . These harvested tumor cell modify adenoviral mediate gene transfer secrete granulocyte-macrophage colony stimulate factor ( GM-CSF ) . Patients administer vaccine one three dose level ( determine total cell yield ) . Vaccinations give weekly three week , follow every week vaccine supply exhaust patient remove study . The patient receive minimum six vaccination , administer vaccine available . During course study , patient test see immune system react vaccination . Testing include bloodwork evaluate immune cell body monthly interval . Skin biopsy may also perform see immune reaction occur injection site . During first course treatment , bone marrow biopsy aspirate may perform monthly . The length time study depend upon number vaccine available whether unacceptable side effect occur .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must pathologically document myelodysplasia acute myelogenous leukemia . The patient myelodysplasia must also : FrenchAmericanBritish ( FAB ) subtype refractory anemia excess blast ( RAEB ) refractory anemia excess blast transformation ( RAEBT ) , normal hypercellular bone marrow . The patient acute myelogenous leukemia must also : candidate myelosuppressive chemotherapy due age comorbid disease , relapse acute myelogenous leukemia refractory standard therapy likely require cytoreductive therapy within 60 day Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Estimated life expectancy 6 month great . Age least 18 year . Greater 4 week chemotherapy , radiotherapy , immunotherapy , systemic glucocorticoid therapy ( nonglucocorticoid hormonal therapy allow ) . Greater 2 month follow bone marrow peripheral blood stem cell transplantation treatment donor lymphocyte infusion ( DLI ) . Uncontrolled active infection . Pregnancy nurse mother . Previous participation adenovirus base trial . The patient myelodysplasia either : FAB subtype refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) , chronic myelomonocytic leukemia ( CMML ) , presence hypocellular bone marrow . Chemotherapy , radiotherapy , immunotherapy , systemic steroid therapy within last 4 week . Active central nervous system ( CNS ) disease . Evidence infection human immunodeficiency virus . Active psychiatric mental illness making informed consent careful clinical followup unlikely .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>AML</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>myelodysplasia</keyword>
	<keyword>vaccine</keyword>
</DOC>